This inventor holds 1 USPTO granted patent. Top assignee: Instituto Chimico Internazionale Dr. Giuseppe Rende S.r.l.. Active years: 1991.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1991
Title: Giuseppe Lo Baido: Innovator in Pharmaceutical Chemistry
Introduction
Giuseppe Lo Baido is a notable inventor based in Rome, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds related to acetazolamide. His work focuses on creating innovative solutions for medical treatments.
Latest Patents
Giuseppe Lo Baido holds a patent for "Acetazolamide-related compounds, process for their preparation, and compounds related to acetazolamide and to its N-methyl derivatives." This patent describes compounds that are inhibitors of carbonic anhydrase, similar to acetazolamide. These compounds are particularly noteworthy because they are well absorbed topically, making them suitable for use as drugs in treating glaucoma.
Career Highlights
Giuseppe Lo Baido is associated with Instituto Chimico Internazionale Dr. Giuseppe Rende S.r.l., where he continues to advance his research and development efforts. His work has the potential to impact the treatment of various medical conditions, particularly those related to eye health.
Collaborations
Some of his notable coworkers include Simonetta Antonaroli and Armandodariano Bianco. Their collaborative efforts contribute to the innovative research being conducted at their institution.
Conclusion
Giuseppe Lo Baido's contributions to pharmaceutical chemistry, particularly through his patent on acetazolamide-related compounds, highlight his role as an important inventor in the field. His work continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile